Validating eNose Measurement of Daily Fiber Intake
eNose Validation Study: Correlating Volatile Organic Compounds With Daily Fiber Intake
1 other identifier
interventional
22
1 country
1
Brief Summary
Monitoring dietary intake and digestion is important for both medical monitoring and assessing the wellness of individuals. Fiber is an important nutrient that is not focused on enough, despite it being an essential nutrient for the bacteria and other micro-organisms that reside in our GI Tracts, known as the microbiome. Ingestion of fermentable soluble and insoluble dietary fiber has been shown to result in the production of short-chain fatty acids (SCFA) by the colonic microbiome. These SCFAs are volatile organic compounds (VOCs) and can be detected in the atmosphere of a bowel movement. We have developed an e-Nose device that once placed in the bathroom records volatile organic compounds (VOCs) from the ambient air. We have demonstrated in an "N of 1" study a strong correlation between the eNose output and grams of daily fiber intake. The current study is being proposed to validate the e-Nose device on a larger population. This is a nonmedical device that is not regulated by the FDA. A total of 40 subjects are invited to participate in this 3-week study. Participants will be asked to complete questionnaires and provide stool and blood samples. The subjects will place the eNose device in their bathroom and record their daily food intake over a 3-week period.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 8, 2022
CompletedFirst Submitted
Initial submission to the registry
November 15, 2022
CompletedFirst Posted
Study publicly available on registry
December 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 13, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
October 13, 2023
CompletedMay 29, 2024
May 1, 2024
11 months
November 15, 2022
May 24, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Accuracy of this device to detect increased intake of fiber
Assessed by comparing percentage change in volatile organic compounds (measured in OHMS) against the daily fiber intake in grams
3 weeks
Secondary Outcomes (3)
Ability of eNose to detect increased production of SCFA- positive correlation between enose signals and each of three SCFA and total SCFA levels in stool
3 weeks
Impact of fiber bar in microbiota composition
3 weeks
Tolerability of prebiotic bar
3 weeks
Study Arms (1)
eNose device use
EXPERIMENTALParticipants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections, and questionnaires over the course of 4 visits during a 3 week period.
Interventions
Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections and questionnaires over the course of 4 visits during a 3-week period.
Eligibility Criteria
You may qualify if:
- Males and females, age 21-65, with no chronic medical diseases (mild and controlled hypertension, and controlled hyperlipidemia are acceptable).
- Willingness to eat 2 prebiotic bar per day for two weeks and collect stool samples three times, provide blood samples twice and complete questionnaires.
You may not qualify if:
- Patients on a restricted diet (e.g., gluten-free diet, Paleo diet, vegetarian or vegan diet)
- Allergy to almonds, flax seed, or coconuts
- Chronic GI disorders (Inflammatory bowel disease, Irritable Bowel Syndrome on regular therapy taking fiber or MiraLAX is acceptable to be enrolled; celiac disease, colon cancer, intestinal resection,)
- Chronic NSAID use (more than 3 days per week)
- Antibiotic use in the last 12 weeks
- BMI \> 35 or \< 18
- Inability to sign an informed consent form
- Non-English speaker
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rush University Medical Center
Chicago, Illinois, 60612, United States
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DEVICE FEASIBILITY
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principle Investigator
Study Record Dates
First Submitted
November 15, 2022
First Posted
December 1, 2022
Study Start
November 8, 2022
Primary Completion
October 13, 2023
Study Completion
October 13, 2023
Last Updated
May 29, 2024
Record last verified: 2024-05